Literature DB >> 18376365

Sorafenib, a systemic therapy for hepatocellular carcinoma.

Nahum Méndez-Sánchez1, Francisco Vásquez-Fernández, Daniel Zamora-Valdés, Misael Uribe.   

Abstract

Hepatocellular carcinoma is a lethal disease that requires a multidisciplinary approach and management. Surgical therapy offers long-term survival; however, few patients are candidates. There has been no accepted systemic therapy for this disease until recently. This article briefly discusses the role of RAS/RAF/MEK/ERK signaling pathway in the pathogenesis of the disease and the promising role of sorafenib for advanced disease.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18376365

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN： 1665-2681            Impact factor:   2.400


  9 in total

1.  Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.

Authors:  Jia-Yu Liu; Tsaiyu Chiang; Chun-Hung Liu; Guann-Gen Chern; Ts-Ting Lin; Dong-Yu Gao; Yunching Chen
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

Review 2.  Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Authors:  Gillian M Keating; Armando Santoro
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 3.  Surgical treatment for hepatocellular carcinoma in cirrhotic patients. Guide to the selection and decision-making process in a context of multimodal strategy.

Authors:  H D González; J Figueras
Journal:  Clin Transl Oncol       Date:  2009-01       Impact factor: 3.405

4.  Repeated Radiofrequency Ablation Combined With Ablated Lesion Elimination and Transarterial Chemoembolization Improves the Outcome of Solitary Huge Hepatocellular Carcinomas 10 m or Larger.

Authors:  Shan Ke; Jun Gao; Jian Kong; Xue-Mei Ding; Hai-Gang Niu; Zong-Hai Xin; Chun-Min Ning; Shi-Gang Guo; Xiao-Long Li; Long Zhang; Yong-Hong Dong; Wen-Bing Sun
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

5.  Difference of polymorphism VEGF-gene rs699947 in Indonesian chronic liver disease population.

Authors:  Neneng Ratnasari; Siti Nurdjanah; Ahmad Hamim Sadewa; Mohammad Hakimi; Yoshihiko Yano
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

6.  A non-smooth tumor margin on preoperative imaging assesses microvascular invasion of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  HangTong Hu; Qiao Zheng; Yang Huang; Xiao Wen Huang; Zhi Cheng Lai; JingYa Liu; XiaoYan Xie; Shi Ting Feng; Wei Wang; Ming De Lu
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

7.  Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.

Authors:  Zeynep Firtina Karagonlar; Dogukan Koc; Evin Iscan; Esra Erdal; Neşe Atabey
Journal:  Cancer Sci       Date:  2016-02-23       Impact factor: 6.716

8.  Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells.

Authors:  Pauline Adjibade; Valérie Grenier St-Sauveur; Miguel Quevillon Huberdeau; Marie-Josée Fournier; Andreanne Savard; Laetitia Coudert; Edouard W Khandjian; Rachid Mazroui
Journal:  Oncotarget       Date:  2015-12-22

Review 9.  Revisiting Platinum-Based Anticancer Drugs to Overcome Gliomas.

Authors:  Jaewan Jeon; Sungmin Lee; Hyunwoo Kim; Hyunkoo Kang; HyeSook Youn; Sunmi Jo; BuHyun Youn; Hae Yu Kim
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.